Cacipliq 20®

Cacipliq 20® is a class III medical device dedicated to wound healing. It is the first product incorporating our innovative RGTA® technology.

Contraindications and warnings exist. Please follow instructions in the package insert. You may read Instructions For Use clicking the link below.

Cacipliq20, dispositif médical pour l'homme

Further information on Cacipliq 20®

Cacipliq 20® is based on the ReGeneraTing Agents (RGTA®) technology, which consists of modified biodegradable sugars.

It protects extracellular matrix proteins, helping to restore their original structure and preserve the natural cellular microenvironment of the wound, as well as the endogenous factors required for tissue regeneration.

Supplied as a sterile solution for easy application twice weekly, Cacipliq 20® promotes rapid and effective wound healing. It is a unique, easy-to-use tissue regeneration solution proven to accelerate wound healing, including in chronic, non-healing ulcers such as those associated with diabetes.

For chronic ulcers showing no tendency to heal after 6 months of conventional care, or untreated ulcers after 12 months including :

  • Bedsores
  • Ulcers following peripheral arterial disease (such as Leriche & Fontaine stage 4)
  • Diabetic ulcers (including amputation)
  • Sterile solution for external use.
  • Spray: box containing a 7.5 ml bottle: around 50 pushes, 3K® pump guaranteeing sterility for 6 months.
  • Kit: 5 ml vial with sterile compress, 2 per box.
  • Preservative free.
  • Reduced healing time
  • Excellent product safety history
  • Easy to use

Publications

The effectiveness of Cacipliq20® has been demonstrated by three clinical trials and numerous case studies.
Below you will find a selection of clinical publications featuring our product.

  • Overview of 10 years of practice with CACIPLIQ20® matrix therapy as a healing agent for hard to heal wounds: Efficacy, cost-effectiveness and future perspectives

    Cacipliq 20 | Media Publications | RGTA technology

    Overview of 10 years of practice with CACIPLIQ20® matrix therapy as a healing agent for hard to heal wounds: Efficacy, cost-effectiveness and future perspectives Background: Chronic, non-healing wounds remain a major challenge for health care practitioners and for society in general, both in terms of the enormous economic burden [...]

  • Cacipliq 20® – Ischemic wound

    Cacipliq 20

    Cacipliq 20® - Ischemic wound First Clinical Pilot Study on critical ischemic leg ulcers with Matrix Therapy ReGeneraTing Agent (RGTA ® ) technology P. DESGRANGES, T. LOUISSAINT, E. ALLAIRE, B. GODEAU, K. KICHENIN, J.- P. BECQUEMIN, D. BARRITAULT Patients with non-healing leg ulcers due to severe limb ischemia and [...]

  • Cacipliq 20® – Chronic wound

    Cacipliq 20

    Cacipliq 20® - Chronic wound Regenerating matrix-based therapy for chronic wound healing: a prospective within-subject pilot study Groah SL, Libin A, Spungen M, Nguyen KL, Woods E, Nabili M, Ramella-Roman J, Barritault D. The aim of this study was to determine whether a skin-specific bioengineered regenerating agent (RGTA) heparan [...]

Questions about OTR3 ?